A Long-term Extension Study of PCI-32765 (Ibrutinib) (NCT01804686)
PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
Who can join: Review the eligibility criteria below.
Location: City of Hope Cancer Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (175 Sites)
Showing the first 25 of 175 sites.
- City of Hope Cancer Center — Duarte, California
- University of California San Diego Medical Center — La Jolla, California
- University of California Los Angeles — Los Angeles, California
- St. Joseph Hospital Center for Cancer Prevention and Treatment — Orange, California
- Stanford University Medical Center — Stanford, California
- Stanford University — Stanford, California
- Norwalk Medical Group — Norwalk, Connecticut
- Northwest Georgia Oncology Centers PC — Marietta, Georgia
- Northwestern University Hospital — Chicago, Illinois
- Indiana University — Goshen, Indiana
- Kansas University Medical Center — Westwood, Kansas
- Louisville Oncology Suburban - Norton Cancer Institute — Louisville, Kentucky
- Dana Farber Cancer Center — Boston, Massachusetts
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Battle Creek Health Systm — Battle Creek, Michigan
- Karmanos Cancer Institute - Wayne State University — Detroit, Michigan
- Washington University — St Louis, Missouri
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- Hackensack University Medical Center — Hackensack, New Jersey
- Weill Medical College of Cornell University — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Southeastern Medical Oncology Center — Goldsboro, North Carolina
- The Ohio State University- James Cancer Hospital — Columbus, Ohio
- Willamette Valley Cancer Center — Eugene, Oregon
- Kaiser Permanente — Portland, Oregon
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
- Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
- Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Chandler, Arizona
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Phoenix, Arizona
Explore by condition: All Chronic Lymphocytic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.